Tegrad (Dolutegravir)

Dolutegravir is a potent integrase strand transfer inhibitor (INSTI) that forms the backbone of modern HIV treatment regimens. This FDA/DOH/WHO-recommended first-line antiretroviral agent, it works by blocking the integrase enzyme, preventing HIV from integrating its genetic material into host cell DNA and effectively halting viral replication.

Key Clinical Features:

Dosing: 50mg once daily for treatment-naive patients; adjusted regimens available for those with integrase resistance or drug interactions. The convenient once-daily formulation enhances adherence and simplifies treatment schedules.

Efficacy: Dolutegravir demonstrates rapid and sustained viral suppression, with many patients achieving undetectable viral loads (below 50 copies/mL) within 4–12 weeks of consistent therapy. Clinical trials show superior efficacy compared to older antiretroviral classes, particularly when paired with complementary nucleoside reverse transcriptase inhibitors (NRTIs).

Tolerability: Generally well-tolerated with a mild adverse effect profile. Common side effects include headache, nausea, diarrhea, dizziness, and sleep disturbances, which typically resolve within the first 2–4 weeks. Weight gain has been documented in some patients, particularly when combined with specific NRTI backbones such as tenofovir or abacavir. Serious adverse effects remain uncommon.

Resistance Profile: High genetic barrier to resistance when used correctly, meaning development of drug-resistant HIV variants is rare with consistent adherence.

Treatment Goals: When taken as prescribed within a complete antiretroviral regimen, dolutegravir reliably suppresses viral load, restores and maintains immune function, prevents AIDS-related complications, and improves long-term health outcomes and life expectancy.

Suitable for treatment-naive and experienced patients, dolutegravir represents a cornerstone agent in contemporary HIV care.